A series of experiments identified both "good" and "bad" gut bacteria, suggesting possible treatments for obesity.
Researchers at the University of North Carolina School of Medicine were on the trail of a protein that was linked to weight gain in mice when an ordinary safety precaution helped reveal what was happening: gut bacteria were at work.
The research, published in Cell Host & Microbe, concerns work on NLRP12, a gene that is produced in several types of immune cells and appears to function as a brake on excessive inflammation. Many studies have linked inflammation to obesity and diabetes; environmental factors including smoking, living in high crime areas, lack of sleep, or disrupted sleep from shift work have been cited as contributing factors in rising rates of these chronic conditions.
The authors of the North Carolina study have published studies that show mice lacking the NLRP12 gene are at risk of excessive inflammation, including colon inflammation and colon cancer. For this study, they fed mice lacking the NLRP12 gene, as well as ordinary mice, a high-fat diet for several months. The NLRP12-knockout mice ate and drank the same amount as the ordinary mice, but accumulated more fat, gained more weight, and showed more signs of insulin resistance.
In these mice, the accumulating fat led to signs of inflammation in the gut, but scientists couldn’t figure out why.
It happened that the scientists had to move some of the mice to another building, which required them to give the mice antibiotics to prevent the spread of disease. And that brought the discovery.
“We noticed that the mice treated with the antibiotics gained less weight than the mice that stayed in the old facility,” said study author Agnieszka Truax, PhD. “That led us to suspect gut bacteria were involved in promoting obesity.”
So the team did more tests with the NLRP12 mice in bacteria-free conditions and found that they did not gain weight. The “bad” bacteria had been fueling the weight gain, and the knockout mice were also somewhat protected from weight gain when housed with control mice because they had “good” gut bacteria.
The experiments revealed the following:
The “good” bacteria, called Lachnospiraceae, contain enzymes that convert carbohydrates and fiber into short-chain fatty acids, which have anti-inflammatory properties that promote gut health. Thus, the authors wrote, treating people with “good” bacteria or these fatty acids could offer a possible treatment for obesity or obesity-driven conditions.
Reference
Truax AD, Chen L, Tam JW, et al. The inhibitory innate immune sensor NLRP12 maintains a threshold against obesity by regulating gut microbiota homeostatis. Cell Host Microbe. 2018;24(3):364. doi: 10.1016/j.chom.2018.08.009.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes
December 20th 2024Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Read More